U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C39H37F6N3O2
Molecular Weight 693.7204
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOMITAPIDE

SMILES

FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)C5=C(C=CC=C5)C6=C4C=CC=C6

InChI

InChIKey=MBBCVAKAJPKAKM-UHFFFAOYSA-N
InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)

HIDE SMILES / InChI
Molecular Formula C39H37F6N3O2
Molecular Weight 693.7204
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:14:35 UTC 2023
Edited
by admin
on Fri Dec 15 17:14:35 UTC 2023
Record UNII
82KUB0583F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LOMITAPIDE
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
AEGR-733
Code English
JUXTAPID
Brand Name English
LOMITAPIDE [MI]
Common Name English
9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-
Systematic Name English
LOMITAPIDE [USAN]
Common Name English
N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE
Systematic Name English
lomitapide [INN]
Common Name English
BMS-201038-01
Code English
Lomitapide [WHO-DD]
Common Name English
LOMITAPIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29703
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
NDF-RT N0000186779
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
FDA ORPHAN DRUG 245907
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
EU-Orphan Drug EU/3/10/823
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
WHO-VATC QC10AX12
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
WHO-ATC C10AX12
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
FDA ORPHAN DRUG 332110
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
Code System Code Type Description
WIKIPEDIA
LOMITAPIDE
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
USAN
TT-134
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
SMS_ID
100000128162
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
INN
9120
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
DAILYMED
82KUB0583F
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
EVMPD
SUB34920
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
RXCUI
1364479
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY RxNorm
IUPHAR
7439
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
CHEBI
72297
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
CHEBI
72299
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
MERCK INDEX
m11671
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
DRUG CENTRAL
4721
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
HSDB
8218
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
PUBCHEM
9853053
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL354541
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
DRUG BANK
DB08827
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
NDF-RT
N0000186778
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY Microsomal Triglyceride Transfer Protein Inhibitors [MoA]
EPA CompTox
DTXSID50171294
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
NCI_THESAURUS
C83891
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
FDA UNII
82KUB0583F
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
LACTMED
Lomitapide
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
CAS
182431-12-5
Created by admin on Fri Dec 15 17:14:35 UTC 2023 , Edited by admin on Fri Dec 15 17:14:35 UTC 2023
PRIMARY
Related Record Type Details
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> NON-INHIBITOR
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN LARGE SUBUNIT
TARGET -> INHIBITOR
In the small unilamellar vesicle (SUV) assay, IC50 values for isolated human MTP 5 nM.
IC50
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
Lomitapide is a weak in vivo CYP3A inhibitor.
WEAK
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> NON-SUBSTRATE
Structure of LOMITAPIDE
EXCRETED UNCHANGED
FECAL
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MINOR
Related Record Type Details
Structure of N-(PIPERIDIN-4-YL)-4'-(TRIFLUOROMETHYL)-BIPHENYL-2-CARBOXAMIDE
METABOLITE -> PARENT
In plasma, M1 was the prominent metabolite that accounted for 5.75% of the total radioactivity in 0 – 24 hours plasma samples. In urine, M1 was the prominent metabolite that accounted for 4.69% of the dose in the 0 –96 hours urine samples. In feces, M1 was the minor metabolite that accounted for 0.49%of the dose in the 0 – 96 hours feces.
FECAL; PLASMA; URINE
Structure of 3,4,5-TRIHYDROXY-6-(4-(9-(2,2,2-TRIFLUOROETHYLCARBAMOYL)FLUOREN-9-YL)BUTANOYLOXY)TETRAHYDROPYRAN-2-CARBOXYLIC ACID, (2S,3S,4S,5R,6S)-
METABOLITE -> PARENT
In plasma, M10+M18 accounted for 9.67% (combined) of the total radioactivity in 0 – 24 hours plasma samples. In urine, M18 was the prominent metabolite, which accounted for 3.77% of the dose in the 0 – 96 hours urine samples.
PLASMA; URINE
Structure of 9-(4-(4-AMINO-1-PIPERIDINYL)BUTYL)-N-(2,2,2-TRIFLUOROETHYL)-9H-FLUORENE-9-CARBOXAMIDE
METABOLITE -> PARENT
MINOR
Structure of N-(2-OXO-4-PIPERIDYL)-2-(4-(TRIFLUOROMETHYL)PHENYL)BENZAMIDE
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of N-(2,2,2-TRIFLUORO-1-HYDROXY-ETHYL)-9-(4-(4-((2-(4-(TRIFLUOROMETHYL)PHENYL)BENZOYL)AMINO)-1-PIPERIDYL)BUTYL)FLUORENE-9-CARBOXAMIDE
METABOLITE -> PARENT
Structure of 9-(4-(4-((2-(4-(TRIFLUOROMETHYL)PHENYL)BENZOYL)AMINO)-1-PIPERIDYL)BUTYL)FLUORENE-9-CARBOXAMIDE
METABOLITE -> PARENT
Structure of 9-(4-(1-OXIDO-4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-N-(2,2,2-TRIFLUOROETHYL)-9H-FLUORENE-9-CARBOXAMIDE
METABOLITE -> PARENT
Structure of 2-(4-(TRIFLUOROMETHYL)PHENYL)BENZAMIDE
METABOLITE -> PARENT
MINOR
PLASMA
Structure of 3,4,5-TRIHYDROXY-6-(4-(9-(2,2,2-TRIFLUOROETHYLCARBAMOYL)FLUOREN-9-YL)BUTOXY)TETRAHYDROPYRAN-2-CARBOXYLIC ACID, (2S,3S,4S,5R,6R)-
METABOLITE -> PARENT
In plasma, M10+M18 accounted for 9.67% (combined) of the total radioactivity in 0 – 24 hours plasma samples. In urine, M10 was the minor metabolite, which accounted for 0.33% of the dose in the 0 – 96 hours urine samples.
PLASMA; URINE
Structure of 9-(4-AMINOBUTYL)-N-(2,2,2-TRIFLUOROETHYL)-9H-FLUORENE-9-CARBOXAMIDE
METABOLITE -> PARENT
In plasma, M5 was the prominent metabolite that accounted for 4.26% of the total radioactivity in 0 – 24 hours plasma samples. In urine, M5 was the prominent metabolite that accounted for 3.47% of the dose in the 0 –96 hours urine samples. In feces, M5 was the minor metabolite that accounted for 0.78% of the dose in the 0 – 96 hours feces.
FECAL; PLASMA; URINE
Structure of 4-(9-(2,2,2-TRIFLUOROETHYLCARBAMOYL)FLUOREN-9-YL)BUTANOIC ACID
METABOLITE -> PARENT
In plasma, M3 was the major metabolite that accounted for 17.3% of the plasma radioactivity. In urine, M3 was the minor metabolite that accounted for 0.34% of the dose in the 0 –96 hours urine samples. In feces, M3 was the minor metabolite that accounted for 1.33 % of the dose in the 0 – 96 hours feces.
FECAL; PLASMA; URINE
Related Record Type Details
Structure of LOMITAPIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Volume of Distribution PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966